Ownership and insider activity for NextCure, Inc. (NXTC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors.
Price
| Price | $6.03 |
| Market Cap | $22M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-10 | Simcere Zaiming, Inc. | S-Sale | 30,000 | $185K |
| 2026-07-31 | ADAR1 Capital Management, LLC | P-Purchase | 8,003 | $38K |
| 2026-07-31 | ADAR1 Capital Management, LLC | P-Purchase | 25,000 | $125K |
| 2026-07-31 | ADAR1 Capital Management, LLC | P-Purchase | 3,300 | $16K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 77,850 | $386K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 100,000 | $490K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 25,000 | $120K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 20,000 | $100K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 20,000 | $100K |
| 2026-07-30 | ADAR1 Capital Management, LLC | P-Purchase | 50,000 | $249K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.4M | $135.2M | $34.1M | $32.8M | $12.3M | $26.6M | $13.1M | $27.7M | $26.0M |
| Short-term Investments | 0 | 0 | $300.5M | $250.7M | $207.3M | $133.3M | $95.2M | $40.9M | $15.8M |
| Receivables | 0 | 0 | 0 | 0 | 0 | $700000 | $800000 | $300000 | $100000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | -$700000 | 0 | 0 | 0 |
| Total Current Assets | $9.4M | $135.8M | $340.0M | $288.0M | $227.8M | $164.0M | $112.7M | $71.8M | $43.7M |
| Property, Plant & Equipment | $10.0M | $11.4M | $12.1M | $15.8M | $14.0M | $16.9M | $13.4M | $8.7M | $5.9M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $19.5M | $147.6M | $356.2M | $306.6M | $242.4M | $184.2M | $128.0M | $80.9M | $50.2M |
| Accounts Payable | $1.1M | $2.5M | $1.9M | $3.9M | $1.9M | $4.3M | $2.3M | $5.4M | $2.0M |
| Short-term Debt | $400000 | $387000 | $1.7M | $1.7M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $3.1M | $10.3M | $15.0M | $10.3M | $6.6M | $9.1M | $6.9M | $9.6M | $10.6M |
| Long-term Debt | $460000 | $73000 | $3.3M | $1.8M | 0 | 0 | 0 | 0 | $4.1M |
| Total Liabilities | $43.9M | $194.6M | $34.7M | $12.9M | $9.0M | $16.6M | $13.6M | $15.4M | $15.2M |
| Retained Earnings | -$24.5M | -$47.3M | -$81.0M | -$117.6M | -$187.0M | -$261.8M | -$324.5M | -$380.1M | -$436.0M |
| Total Equity | -$24.4M | -$46.9M | $321.5M | $293.7M | $233.4M | $167.5M | $114.4M | $65.5M | $34.9M |
| Total Debt | $964000 | $587000 | $5.1M | $3.5M | 0 | $7.1M | $6.6M | $5.9M | $5.2M |
| Net Debt | -$7.5M | -$134.6M | -$329.5M | -$280.0M | -$219.6M | -$152.8M | -$101.7M | -$62.7M | -$36.7M |
| Working Capital | $6.3M | $125.5M | $325.0M | $277.7M | $221.2M | $154.9M | $105.8M | $62.2M | $33.2M |
Financial Health
| Debt / Equity | 0.35 |
| Current Ratio | 3.47 |
Profitability
| Return on Equity | -175.46% |
| Return on Invested Capital | -259.91% |
| Return on Assets | -188.98% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · BOLD · INTS · ITRM · JSPR · PLUR · PSTV
Explore sector: Healthcare · Biotechnology
More sections of NXTC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks